Dare Bioscience, Inc. (DARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on July 17, 2026, regarding an event that occurred on July 13, 2026. The Company is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock is registered on the Nasdaq Capital Market.
Key Financial Metrics
The filing references specific financial thresholds that triggered the regulatory notice:
- Stockholders' Equity: Less than $2.5 million as reported in the Form 10-Q for the period ended March 31, 2026.
- Market Value of Listed Securities: Below the alternative requirement of $35 million as of July 13, 2026.
- Net Income: Below the alternative requirement of $500,000 from continuing operations as of July 13, 2026.
The filing text does not provide specific values for revenue, cash flow, operating margins, or debt levels.
Material Changes and Delisting Notice
On July 13, 2026, the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that it no longer complies with Nasdaq Listing Rule 5550(b). Consequently, the Company's common stock is subject to delisting from the Nasdaq Capital Market.
Outlook, Management Commentary, and Risks
Management Action: The Company intends to timely request a hearing before a Nasdaq Hearing Panel. This request will stay the suspension and delisting of the common stock pending the Panel's decision and any potential extension period.
Risks and Contingencies:
- There is no assurance that the Panel will grant a request for an extension to evidence compliance.
- Even if an extension is granted, there is no assurance the Company will regain compliance within that period.
- There is no assurance the Company will be successful in maintaining its listing on Nasdaq.
Key Facts for Investor Verification
- Verify the Company's current stockholders' equity and whether it remains below the $2.5 million threshold.
- Monitor the status of the hearing request with the Nasdaq Hearing Panel and any subsequent rulings.
- Check for any announcements regarding a plan to regain compliance, such as a reverse stock split or capital raise.
- Review the most recent Form 10-Q (ended March 31, 2026) for detailed financial statements not included in this 8-K.